Neo Modulus, a developer of regenerative implantable medical devices based in Suzhou, has reportedly raised “hundreds of millions” of renminbi in a Series B financing round. The round was led by SND Financial Holdings, with participation from JM Capital, CDH Investments, Hui Ding Capital, 10Fund, and Boya Clivia Venture Capital. The proceeds will be directed towards clinical studies and the global development of the company’s product pipeline.
Company Background and Technology
Founded in 2017, Neo Modulus is known for its front-end raw materials design and development, as well as key process preparation technology. The company has established partnerships with prestigious scientific institutions, including Albert Ludwig University of Freiburg. Neo Modulus operates research and development and manufacturing bases in Suzhou, Weifang, and Taicang, a medical center in Beijing, and a laboratory at Albert Ludwig University of Freiburg. This extensive network supports the company’s innovative product pipeline, which covers a wide range of clinical departments, including oral, ophthalmology, otolaryngology, surgery, reproductive medicine, sports medicine, and more.
Product Development
Neo Modulus is currently developing articular cartilage regeneration products. These products are designed to promote the regeneration of true transparent cartilage and subchondral bone without the use of cells, growth factors, or other drugs. Additionally, the company is working on next-generation biodegradable vascular graft products, which are particularly suitable for dialysis patients with chronic kidney disease. These innovations highlight Neo Modulus’s commitment to advancing regenerative medicine and improving patient outcomes.-Fineline Info & Tech
